Viridian Therapeutics is a clinical-stage biopharmaceutical company focused on autoimmune and rare diseases, with no approved products yet. Viridian's near-term pipeline is almost entirely centered on thyroid eye disease (TED), a rare autoimmune disorder causing eye inflammation, bulging, double vision, and potential blindness. Viridian has two TED candidates, both targeting the IGF-1R pathway — the same mechanism as Amgen's Tepezza, the only FDA-approved TED treatment. Veligrotug is an IV anti-IGF-1R antibody that completed two pivotal phase 3 trials (THRIVE and THRIVE-2), both meeting primary and secondary endpoints. Viridian filed a BLA with the FDA in October 2025, which was accepted under Priority Review with a PDUFA date of June 30, 2026. Elegrobart is a subcutaneous anti-IGF-1R antibody with a half-life four to five times longer than veligrotug, enabling at-home self-injection every four to eight weeks. Two pivotal phase 3 trials (REVEAL-1 and REVEAL-2) completed enrollment, with topline data expected in Q1 and Q2 2026. Beyond TED, Viridian is developing FcRn inhibitors (VRDN-006 in phase 1, VRDN-008 pre-IND) targeting a broad range of autoimmune diseases, and an early-stage anti-TSHR antibody for TED and Graves' disease. Viridian funds itself through capital raises and licensing deals, outsources all manufacturing to CDMOs, and plans to commercialize veligrotug directly in the U.S. if approved.